← Back to all trials
Not Yet Recruiting
NCT07806019
Metformin in Parkinson's Disease: Safety and Efficacy
Conditions: Parkinsons Disease (PD)
Sex: All
Ages: 50 Years – 70 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 70
Sponsor: Jinnah Medical & Dental College
Summary
This study will evaluate whether metformin when it will be given to patients with Parkinson's disease along with standard therapy (levodopa carbidopa) will improve motor symptoms and decreases levels of alpha synuclein and MDA in patients with PD as compare to PD patients receiving only standard therapy (levodopa carbidopa)
Eligibility Criteria
Inclusion Criteria: :
Male and female patients diagnosed with primary PD age 50-70 years receiving levodopa + carbidopa. Diagnosis will be made in accordance with movement disorder society clinical diagnostic criteria for Parkinson's disease
Exclusion Criteria:
Secondary Parkinsonism co-morbid (such as Diabetes mellitus, Cardio-vascular diseases, Senile tremors, Wilson's disease, Cancers etc.) Pregnant and lactating mothers Sensitivity to metformin Lactic acidosis History of alcohol use
Source: ClinicalTrials.gov (NCT07806019). StuddyBuddy aggregates publicly available trial information.
